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a  b  s  t  r  a  c  t
Background: Gaucher disease is an inborn, autosomal recessive error of the metabolism
which belongs to the group of lysosomal storage disorders.
Objective: This work reports on the treatment of Gaucher disease in several members of the
same  family from the countryside of Maranhão.
Methods: This was an observational, retrospective and prospective, descriptive case study
about the efﬁcacy of enzyme replacement therapy.
Results: The results showed that women were more affected (80% of patients) by the disease,
age at diagnosis ranged from 24 to 33 years, the predominant ethnicity was mulatto (80%)
and all cases were classiﬁed as type 1. The diagnosis of these patients was performed by
measuring the levels of glucocerebrosidase and chitotriosidase enzymes and conﬁrmed by
genotyping. All patients suffering from Gaucher disease had low glucocerebrosidase levels.
Before replacement therapy, hepatosplenomegaly was the most common clinical mani-
festation (100%) and osteopenia was seen in 80% of the cases. Regarding hematological
manifestations, anemia and leukopenia were found in 40% of patients at diagnosis; however
the  hemoglobin and leukocyte levels were normalized after four years of therapy. Throm-
bocytopenia, observed in 20% of cases, was normalized after the second year of treatment.
Conclusion: In these cases, despite gaps in the treatment as the family resides in the rural
region  of the state, the patients with Gaucher disease showed satisfactory therapeutic
response over time.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.ntroduction
aucher disease (GD) was ﬁrst described in 1882. It is a reces-
ive autosomal lysosomal storage disorder which is caused by
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of undigested glycolipids and leads to histological changes,
especially evident in organs that are rich in elements of the
monocytic-phagocyte immune system (spleen, liver and bone
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – Family heredogram showing segregation of the374  rev bras hematol hem
marrow).1,2 In more  severe cases, this disease can affect the
lungs, kidneys and central nervous system (CNS).3–5
GD is classiﬁed into three types according to the presence
or absence of primary disease in the CNS: Type 1, the non-
neuropathic form is the most common, Type 2, presents with
serious impairment of CNS in childhood, and Type 3, with mild
impairment of the CNS in adolescence or early adulthood.6
The most common type is also called the adult’s non-
neuropathic chronic form (90–99% of cases). It is prevalent
among cases of Ashkenazi Jews, affecting about 1:450 of these
individuals and 1:40,000 of the general population.7,8
Diagnosis is by biochemical tests that can demonstrate
glucocerebrosidase deﬁciency with enzyme activity in leuko-
cytes and cultured skin ﬁbroblasts below 10% of the normal
level. These values are determined by laboratory tests or by
skin biopsy.4,9 A bone marrow biopsy is widely used to iden-
tify Gaucher cells, however, it is not pathognomonic and it
can often lead to wrong diagnoses such as chronic myeloid
leukemia, myeloblastic leukemia, Niemann-Pick disease,
Hodgkin’s disease and non-Hodgkin nodular lymphoma.7
GD is transmitted by autosomal recessive inheritance
deﬁned by mutations in the beta-glucosidase (GBA) gene that
is responsible for encoding the glucocerebrosidase enzyme.
This gene is located on the long arm of chromosome 1 (q21
region). The presence of two mutant alleles conﬁrms diagno-
sis. The most prevalent mutations in this disease are N370S
and L444P.10
The main clinical manifestations of GD include: hep-
atosplenomegaly, hematological disorders (anemia, thrombo-
cytopenia and, more  rarely, leukopenia), bone injuries and
CNS impairment.11 Besides these symptoms, patients may
also be affected by non-speciﬁc symptoms such as insomnia,
headaches, chronic pain, paresthesia, depression and diffuse
musculoskeletal pain. These patients do not have a good
response to enzyme replacement therapy (ERT).
In addition, psychiatric symptoms, and more  subtle, initial
cognitive and motor changes may also appear.12,13
The treatment of most symptomatic patients is mainly
supportive care with painkillers. Thus, the Brazilian Ministry
of Health introduced ERT for GD in 1990 through the Spe-
cial Drug Program, producing a protocol of correct therapeutic
procedures.14,15
ERT has signiﬁcantly changed treatment for Gaucher dis-
ease with reduced morbidity and improved quality of life and
thus this is currently the treatment of choice; it is free through
the Brazilian National Health Service.16
Herein we report the response to ERT of a group of patients
with Gaucher disease in the same family from São Domingos
do Maranhão. São Domingos do Maranhao is located 380 km
from the capital, São Luís, and according to the latest census,
the population is 33,506 people.17,18 This study was approved
in all respects by the Evaluation Committee for Research and
Training (CAPPE) of HEMOMAR.
Case  reportThis study included ﬁve patients with the diagnosis of GD of a
family of 11 individuals from the municipality of São Domin-
gos do Maranhão. All were treated by the Hematology andtwo mutations.
Hemotherapy Center of Maranhão (HEMOMAR) located in the
state capital.
The instrument used for data collection included two forms
to collect clinical, laboratory, radiological and socioeconomic
data, besides the medical records from 2003 to 2010. Data
on gender, race, age at diagnosis, occupation, classiﬁcation
according to the disease type, weight, height, glucocerebrosi-
dase and chitotriosidase enzyme levels and type of genetic
mutation were obtained from medical records.
The family heredogram below shows three individuals
heterozygous for GD (I1, I2 and II2), ﬁve compounded het-
erozygous for GD (II1, II3, II4, II6 and II8) and three normal
individuals (II5, II7 and II9) (Fig. 1).
All patients had diagnostic conﬁrmation of GD by mea-
surement of glucocerebrosidase enzyme activity. The affected
family members (heterozygotes) are: II1, II3, II4, II6, II8, all
featuring the same genotype (N370S/?). Patient II2 is the
only member of the second heterozygous generation for the
unidentiﬁed allele (?), whose genotype is normal/? The other
members of the second generation: II5, II7 and II9 are normal,
with no signiﬁcant changes in their enzyme measurements.
Parents I1 and I2 are heterozygous for N370S and ? respec-
tively. All patients affected by GD showed very high levels of
chitotriosidase, except for Patient II4 (Table 1).
There is predominance of females (80%). Table 2 shows that
all patients were diagnosed in adulthood with ages between 24
and 33 years and a mean of 28.4 years and are predominantly
mulatto with only one Caucasian patient. Most patients are
agricultural laborers (80%). All patients are type 1 or compose
a characteristic non-neuropathic clinical picture.
Data on the determination of glucocerebrosidase and chi-
totriosidase levels were collected from medical records. Fig. 2
shows that only Patient #3 had a normal chitotriosidase level,
while the others had high levels of this enzyme before start-
ing ERT. After about seven years (in case of Patients #1–4) and
three years (Patient #5) of ERT, all patients had chitotriosidase
levels within the normal range.
The presence of anemia, leukopenia, thrombocytopenia,
splenomegaly, hepatomegaly and skeletal changes were eval-
uated prior to and after starting ERT between 2003 and 2010.
Anemia was identiﬁed in 40% of patients at diagno-
sis (Fig. 3). However, after four years of ERT, there was
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Table 1 – Glucocerebrosidase and chitotriosidase levels and the genotype of all family members.





I1 7.9 12.8 Heterozygous for N370S Normal/N370Sa
I2 5.26 5.6 Heterozygous for? Normal/?a
II1 1.4 3150 Compound heterozygous N370S/?
II2 4.0 2 Heterozygous for? Normal/?
II3 2.1 7462 Compound heterozygous N370S/?
II4 0.39 48 Compound heterozygous N370S/?
II5 10.1 – Normal Normal/normala
II6 1.2 8694 Compound heterozygous N370S/?
II7 10.2 12.9 Normal Normal/normala
II8 0.5 1897 Compound heterozygous N370S/?
II9 6.88 – Normal Normal/normala
a Patients in whom the genotype was deduced according to the enzymatic dosage.
? means unidentiﬁed mutation.
The normal value used by the laboratory that analyzed the activity of glucocerebrosidase is >3.2 nmol/mg/h.
Table 2 – Sociodemographic characteristics and clinical






20–25 years 1 60
26–30 years 3 20
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Figure 2 – Distribution of chitotriosidase levels beforeFarmer 4 80
Housewife 1 20
ormalization of hemoglobin levels in all patients with these
evels remaining normal until 2010, except for Patient #4, who
howed a decreased hemoglobin level in 2008.At diagnosis, 40% of patients were leukopenic but after four
ears of ERT, no patient had leukopenia. In 2008, Patients #1
nd #4 presented with leukopenia.
Table 3 – Bone impairment in patients with Gaucher
disease before and after enzyme replacement therapy
(ERT).
n %
Imaging changes after ERT
Absent 1 20
Osteopenia 4 80
Avascular necrosis 1 20
Deformities in Erlenmeyer ﬂask 1 20
Lytic lesions 1 20
Fractures 1 20
Image changes before ERT
Absent 2 60
Avascular necrosis 1 20
Deformities in Erlenmeyer ﬂask 2 60enzyme replacement treatment and in 2010.
At diagnosis, 20% of patients had thrombocytopenia which
was resolved after the second year of ERT with all patients
having normal platelet counts. It is noteworthy that Patient
#1 had no thrombocytopenia before ERT however the platelet
count dropped in 2006.
At diagnosis, there was bone impairment in 80% of
patients. The most common osseous impairment prior the
ERT was osteopenia, present in 80% of patients (Table 3). It
seems that bone impairment is still present during ERT, with
20% of cases having Erlenmeyer ﬂask deformity and 20% hav-
ing avascular necrosis. Some patients had more  than one
lesion before the ERT but there were no imaging changes in
60% of cases after ERT (Table 3).
Visceromegalies and hepatosplenomegaly were present in
all of the patients before ERT however at the end of this study
only 20% of patients had splenomegaly.
There was a signiﬁcant gain in body mass of patients after
starting ERT, except for Patient #5.
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Figure 3 – Distribution of hemoglobin levels in patients with Gaucher disease between the years 2003 and 2010.Discussion
Gaucher disease is pan-ethnic, but with a high incidence in
the population of Ashkenazi Jews, involving 1:450 live births
compared to just 1:40.000 in the general population.7 Four
alleles (N370S, L444P, 84GG, IVS2 + 1) account for most of the
mutations that cause the disease, in particular in Ashkenazi
Jews due to the tradition of marrying within the same ethnic
group.7
This study focuses on a rare health problem of one family
in Maranhão. According to reports, there is a very pertinent
relationship to the origin of this family conﬁrmed by the mem-
bers who reported Jewish ancestry, but denied any relationship
between the parents.7
The diagnosis of GD should be based on the measurement
of the glucocerebrosidase enzyme in the presence of sugges-
tive clinical manifestations of the disease. When this does
not conﬁrm diagnosis, other methods are used, such as high
levels of chitotriosidase enzyme and family medical history,
bone marrow biopsy, molecular analysis (genotyping), non-
speciﬁc imaging results and laboratory exams.19 In this family,
four members (36.3%) had glucocerebrosidase activity sugges-
tive of GD, four (36.3%) levels suggesting heterozygosity and
two (18.1%) cases had normal enzyme activity. Family mem-
ber II3, despite not having enzymatic values between 0 to
1.9 nmol/h/mg protein, had conﬁrmed GD diagnosis.
There is a strong relationship between these mutations and
clinical manifestations of the disease. Thus, the genotype can
help predict severity in patients. For instance, homozygosity
for the N370S allele is associated with a less severe pheno-
type, although with wide clinical variety. Heterozygosity for
N370S is protective against impairment of the SNC.19 The fam-
ily members with GD were II1, II3, II4, II6, II8, all of whomhad the N370S/? genotype (compound heterozygote). Family
member II2 is female, heterozygous with the N/? genotype.
The other individuals (II5, II7 and II9) are normal, with no
signiﬁcant changes in their enzyme levels.
An analysis of the probability of individuals having GD in
a family whose parents are heterozygous shows that 25% of
births are compound heterozygous (affected by GD), 50% het-
erozygous (one allele with a mutation of the GBA gene) and
25% are normal. In this case, of the total of nine children, ﬁve
(55.5%) are compound heterozygotes for GD, thus showing the
peculiarity of this case.
In a study conducted in Maranhão, 13 in a total of 14
patients with GD had documented genotyping. The N370S/?
genotype was found in 42.2% of cases, whereas the presence
of the N370S mutation was identiﬁed in more  than two  thirds
of the patients studied.15 In a study from Santa Catarina State,
the N370S allele was identiﬁed in 60% of cases, with homozy-
gosity in only one case. The L444P mutant allele was present
in heterozygosis with the N370S mutation in 20% of patients.7
GD is inherited in an autosomal pattern and can affect both
genders. With a total of ﬁve patients affected by GD and all
members of the same family, in this study there was pre-
dominance of female patients (80%). In Maranhão, females
are predominant in 64.3% of cases.15 In one of the most
important studies on GD, there was a slight predominance
of females at 54%.20 In Brazil, out of the total of 551 patients
registered and accompanied by the Gaucher Registry, 58% of
patients are female. The situation is similar worldwide, with
53% females and 47% males of a total of 4764 patients enrolled
in registries.21This study reported that all patients are mulattoes except
for one patient who is Caucasian. In a survey conducted in
the state of São Paulo, a 62.2% rate of non-white patients was
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19. Ferreira JS, Ferreira VL, Ferreira DC. Estudo da doenc¸a derev bras hematol hemot
ERT was introduced in 1991 and has been shown to
everse or ameliorate many  of the visceral and hema-
ological manifestations of GD. ERT also improves bone
anifestations, including bone crises, bone pain, and appear-
nce of new osteonecrosis in the joints and pathological
ractures, and improves bone mineral density to varying
egrees.23
After measuring enzyme levels and genotyping, all ﬁve
atients affected by the disease in this family fall into the
linical classiﬁcation of type 1 GD. Studies report that most
atients are type 1 (94–96% type 1), less than 1% are type 2
nd about 5% are type 3.8,24
Anemia has been reported in the literature in between
0%15 and 100%7 of cases. In the International Collaborative
aucher Group (ICGG) report, anemia was present in 52% of
ases before treatment with imiglucerase.21 In the study in
anta Catarina State, leukopenia was also present in 50% of
ases.7 In an Italian study, hemoglobin, and leukocyte and
latelet counts remained stable after ERT.25 In several stud-
es thrombocytopenia was present: there was a signiﬁcant
ercentage (50% of cases) in Maranhão.15 In one study, throm-
ocytopenia was found in 56.25% of 128 patients,26 partially
isagreeing to data found in this study.
Hepatosplenomegaly was the most common clinical fea-
ure observed in patients with GD in the current study. In a
tudy in Maranhão, hepatomegaly and splenomegaly affected
6.6% and 83.3% of patients, respectively.15 In another study,
epatosplenomegaly was the most common pathological ﬁnd-
ng at physical examination (80% of cases).7
There is a wide spectrum of skeletal complications
elated to GD, ranging from asymptomatic osteopenia to
steonecrosis, with secondary articular degeneration.27 A
tudy conducted in the state of Santa Catarina, detected bone
bnormalities in 75% of patients with the most common being
steopenia in 40% of cases, followed by avascular necrosis
n 30% and Erlenmeyer ﬂask deformity in 20%.7 In a study
onducted in Spain, 40% of patients complained of diffuse
one pain.28 In a study carried out in Israel, after four years
f ERT, there was a signiﬁcant improvement in spleen and
iver volumes, hemoglobin and platelet counts and Z-scores
or lumbar spine and femur.23
Before starting the ERT, 80% of patients had a body mass
ndex (BMI) between 18.5 and 24.9 kg/m2. Only one of the
atients had a BMI  between 25 and 29.9 kg/m2. However,
n 2010, seven years after starting the ERT, 60% of patients
ntered the overweight threshold and 40% had normal BMIs.
mong those considered normal, only one lost body mass
Patient #5 – from 27.6 kg/m2 to 23.8 kg/m2).
In conclusion, ﬁve members of this family had GD and were
ollowed up at HEMOMAR. The age at diagnosis and classiﬁca-
ion of the GD type correlated to cases registered in the State
f Maranhão with the prevalence of the N370S mutation. ERT
mproved hematological indexes, hepatosplenomegaly and
he quality of life of these patients.
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